Access the full text.
Sign up today, get DeepDyve free for 14 days.
J. Ferlay, Hai-rim Shin, F. Bray, D. Forman, C. Mathers, D. Parkin (2010)
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008International Journal of Cancer, 127
R. Roskoski (2013)
Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition.Pharmacological research, 68 1
D. Galetta, A. Rossi, S. Pisconti, G. Colucci (2012)
The emerging role of ALK inhibitors in the treatment of advanced non-small cell lung cancerExpert Opinion on Therapeutic Targets, 16
M. Soda, Y. Choi, M. Enomoto, S. Takada, Y. Yamashita, S. Ishikawa, Shin-ichiro Fujiwara, Hideki Watanabe, K. Kurashina, H. Hatanaka, M. Bando, S. Ohno, Y. Ishikawa, H. Aburatani, T. Niki, Y. Sohara, Y. Sugiyama, H. Mano (2007)
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancerNature, 448
M. Börger, M. Gosens, Jwm Jeuken, Lclt Kempen, C. Velde, J. Krieken, I. Nagtegaal (2007)
Signet ring cell differentiation in mucinous colorectal carcinomaThe Journal of Pathology, 212
S. Rodig, M. Mino‐Kenudson, S. Dacic, B. Yeap, A. Shaw, J. Barletta, Hannah Stubbs, Kenny Law, N. Lindeman, E. Mark, P. Janne, T. Lynch, B. Johnson, A. Iafrate, L. Chirieac (2009)
Unique Clinicopathologic Features Characterize ALK-Rearranged Lung Adenocarcinoma in the Western PopulationClinical Cancer Research, 15
L. Monjour, I. Vouldoukis, B. Ogunkolade, C. Hetzel, M. Ichen, D. Frommel (1988)
Vaccination and treatment trials against murine leishmaniasis with semi-purified Leishmania antigens.Transactions of the Royal Society of Tropical Medicine and Hygiene, 82 3
S. Krishnamurthy, W. Woodward, W. Yang, J. Reuben, J. Tepperberg, D. Ogura, S. Niwa, L. Huo, Y. Gong, R. El-Zein, A. González-Angulo, M. Chávez-MacGregor, R. Alvarez, A. Lucci, V. Valero, N. Ueno (2013)
Status of the anaplastic lymphoma kinase (ALK) gene in inflammatory breast carcinomaSpringerPlus, 2
S. Ou, E. Kwak, C. Siwak-Tapp, Joni Dy, K. Bergethon, Jeffrey Clark, D. Camidge, B. Solomon, Robert Maki, Y. Bang, Dong-Wan Kim, James Christensen, Weiwei Tan, Keith Wilner, Ravi Salgia, A. Iafrate (2011)
Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 6 5
A. Shaw, B. Yeap, M. Mino‐Kenudson, S. Digumarthy, D. Costa, R. Heist, B. Solomon, Hannah Stubbs, S. Admane, U. McDermott, J. Settleman, Susumu Kobayashi, E. Mark, S. Rodig, L. Chirieac, E. Kwak, T. Lynch, A. Iafrate (2009)
Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 26
John Park, R. Kerbel, G. Kelloff, J. Barrett, B. Chabner, D. Parkinson, Jonathan Peck, R. Ruddon, C. Sigman, D. Slamon (2004)
Rationale for Biomarkers and Surrogate End Points in Mechanism-Driven Oncology Drug DevelopmentClinical Cancer Research, 10
A. Weickhardt, D. Aisner, W. Franklin, M. Varella-Garcia, R. Doebele, D. Camidge (2013)
Diagnostic assays for identification of anaplastic lymphoma kinase‐positive non–small cell lung cancerCancer, 119
M. Mino‐Kenudson, L. Chirieac, Kenny Law, J. Hornick, N. Lindeman, E. Mark, David Cohen, B. Johnson, P. Jänne, A. Iafrate, S. Rodig (2010)
A Novel, Highly Sensitive Antibody Allows for the Routine Detection of ALK-Rearranged Lung Adenocarcinomas by Standard ImmunohistochemistryClinical Cancer Research, 16
Eva Lin, Li Li, Y. Guan, R. Soriano, Celina Rivers, S. Mohan, A. Pandita, Jerry Tang, Z. Modrušan (2009)
Exon Array Profiling Detects EML4-ALK Fusion in Breast, Colorectal, and Non–Small Cell Lung CancersMolecular Cancer Research, 7
D. Aisner, Teresa Nguyen, D. Paskulin, A. Le, J. Haney, Nathan Schulte, F. Chionh, J. Hardingham, J. Mariadason, N. Tebbutt, R. Doebele, A. Weickhardt, M. Varella-Garcia (2013)
ROS1 and ALK Fusions in Colorectal Cancer, with Evidence of Intratumoral Heterogeneity for Molecular DriversMolecular Cancer Research, 12
P. Bavi, Z. Jehan, R. Bu, S. Prabhakaran, N. Al‐Sanea, F. Al-Dayel, M. Al-Assiri, T. Al-Halouly, R. Sairafi, S. Uddin, K. Al-Kuraya (2013)
ALK gene amplification is associated with poor prognosis in colorectal carcinomaBritish Journal of Cancer, 109
S. Taghavi, S. Jayarajan, A. Davey, A. Willis (2012)
Prognostic significance of signet ring gastric cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 28
S. Popat, D. Gonzalez, T. Min, J. Swansbury, M. Dainton, James Croud, A. Rice, A. Nicholson (2012)
ALK translocation is associated with ALK immunoreactivity and extensive signet-ring morphology in primary lung adenocarcinoma.Lung cancer, 75 3
Ryu Jokoji, Takashi Yamasaki, S. Minami, K. Komuta, Y. Sakamaki, K. Takeuchi, M. Tsujimoto (2010)
Combination of morphological feature analysis and immunohistochemistry is useful for screening of EML4-ALK-positive lung adenocarcinomaJournal of Clinical Pathology, 63
Y. Mossé, A. Wood, J. Maris (2009)
Inhibition of ALK Signaling for Cancer TherapyClinical Cancer Research, 15
M. Tsujii, S. Kawano, R. Dubois (1997)
Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential.Proceedings of the National Academy of Sciences of the United States of America, 94 7
K. Kwon, K. Shim, E. Song, J. Choi, Seong-Eun Kim, Hye-Kyung Jung, S. Jung (2013)
Clinicopathological characteristics and prognosis of signet ring cell carcinoma of the stomachGastric Cancer, 17
L. Tanoue (2012)
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung CancerYearbook of Pulmonary Disease, 2012
E. Yi, J. Boland, J. Maleszewski, A. Roden, Andre Oliveira, M. Aubry, M. Erickson-Johnson, B. Caron, Yan Li, H. Tang, Shawn Stoddard, J. Wampfler, K. Kulig, Ping Yang (2011)
Correlation of IHC and FISH for ALK Gene Rearrangement in Non-small Cell Lung Carcinoma: IHC Score Algorithm for FISHJournal of Thoracic Oncology, 6
H. Niu, Qi-ming Zhou, Fang Wang, Qiong Shao, Y. Guan, X. Wen, Li-zhen Chen, Qi-sheng Feng, Wei Li, Y. Zeng, Xiao-shi Zhang (2013)
Identification of anaplastic lymphoma kinase break points and oncogenic mutation profiles in acral/mucosal melanomasPigment Cell & Melanoma Research, 26
N. Thangue, D. Kerr (2011)
Predictive biomarkers: a paradigm shift towards personalized cancer medicineNature Reviews Clinical Oncology, 8
D. Camidge, M. Theodoro, Delee Maxson, M. Skokan, T. O'Brien, Xian Lu, R. Doebele, A. Baron, M. Varella-Garcia (2012)
Correlations between the percentage of tumor cells showing an anaplastic lymphoma kinase (ALK) gene rearrangement, ALK signal copy number, and response to crizotinib therapy in ALK fluorescence in situ hybridization–positive nonsmall cell lung cancerCancer, 118
T. Grob, U. Heilenkötter, S. Geist, P. Paluchowski, C. Wilke, F. Jaenicke, A. Quaas, W. Wilczak, M. Choschzick, G. Sauter, A. Lebeau (2012)
Rare oncogenic mutations of predictive markers for targeted therapy in triple-negative breast cancerBreast Cancer Research and Treatment, 134
Objectives: ALK-EML4 translocation is an established driver aberration in non-small cell lung cancer (NSCLC), with reported predilection for cases with signet ring histology. We assessed the presence of anaplastic lymphoma kinase (ALK) gene rearrangements in signet ring cancers arising in the stomach and colon. Methods: Histologically confirmed cases of signet ring adenocarcinoma of the stomach or the colon were identified. The presence of the classic ALK and EML4 fusion gene was initially determined by fluorescence in-situ hybridization (FISH) technique. Immunohistochemistry (IHC) was performed using two previously validated antibodies, ALK1 clone (1:100; DAKO) and 5A4 (Novocastra, Leica Biosystems) along with positive controls of ALK-translocated lung cancer. Results: We employed 42 cases of signet ring carcinoma diagnosed between 2001 and 2011; 25 gastric and 17 colon cancer. Median age 63.3 years; male/female 17/25; race, black 47.5%, white 47.5%, others, 5%; stage I, 21.4%; stage II, 31%; stage III, 26.2%; stage IV, 21.4%. One of 42 cases (2.3%) was positive for ALK translocation by FISH using the standard criteria of at least 15% positive cells for the break-apart signal (50–70 cells enumerated per case). Using a less restrictive cut-off of 10% positive cells, 7 cases (16%) were considered possibly positive. None of the ‘possibly positive’ cases was found to harbor ALK translocation by another molecular testing approach (IHC). IHC with two previously validated monoclonal antibodies showed 0 of 42 (0%) cases positive. Conclusions: ALK gene rearrangement is very rare in gastrointestinal cancers and enrichment strategy focusing on signet ring cell histology did not significantly improve the detection rate.
Therapeutic Advances in Medical Oncology – SAGE
Published: Jan 21, 2015
Keywords: ALK rearrangement,ALK-EML4 fusion,colon,signet ring cell cancer,stomach
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.